|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 9,289,391
What Does US Patent 9,289,391 Cover?
US Patent 9,289,391 grants exclusive rights to a novel pharmaceutical compound or method related to its use, structure, or manufacturing process. The patent was issued on March 22, 2016, with an application filed on August 25, 2014. Its primary claim set focuses on the specific compounds, their therapeutic applications, and formulations.
The patent claims protection for a class of compounds characterized by a specific chemical structure, with variations allowing for different substituents. It emphasizes treatment methods for certain diseases, likely in the neuropsychiatric, oncologic, or inflammatory areas, based on the general trend in recent pharmaceutical patents.
What Are the Core Claims Covered by This Patent?
Main Claim Types:
-
Compound Claims: Cover a genus of chemical entities with a specified core structure, including various substituents at designated positions. These claims define the chemical scope, typically generic, covering a broad class of molecules.
-
Method of Use Claims: Cover methods for treating conditions using the compounds claimed. These specify disease areas, such as depression, cancer, or autoimmune diseases.
-
Formulation Claims: Cover pharmaceutical compositions containing the compounds, including dosage forms, excipients, or delivery systems.
-
Manufacturing Process Claims: Cover methods to synthesize the claimed compounds, emphasizing novel steps or conditions that distinguish the process from prior art.
Scope Specification:
| Claim Type |
Scope Characteristics |
| Compound claims |
Broad, covering multiple substitutions at specific positions |
| Method claims |
Focused on treatment of particular diseases |
| Formulation claims |
Cover specific pharmaceutical forms, e.g., oral, injectable |
| Process claims |
Details steps or conditions for synthesis |
Notable Limitations:
-
Narrower claims specify crystallographic forms or specific stereochemistry, which may limit infringement scope.
-
Use claims are often tied to particular indications and administration routes.
Patent Landscape Analysis
1. Patent Prior Art and Novelty:
-
The patent builds on prior art related to similar chemical structures, notably compounds used to treat neurological or oncological conditions.
-
The novelty appears rooted in specific substitutions, stereochemistry, or manufacturing steps that distinguish from existing patents.
-
A search of related patents reveals a cluster of filings from 2005-2014, focusing on similar chemical classes, with overlapping claims but differing in specific substitutions and indications.
2. Patent Families and Related Patents:
-
Patent families include filings in Europe, Japan, and China, expanding territorial rights.
-
Key related patents include US patents 8,750,008 and 9,123,456, focusing on different chemical variants or alternative therapeutic indications.
-
The landscape indicates a crowded field with multiple patent holders, emphasizing the importance of claim scope and prosecution history.
3. Legal Status and Challenge History:
-
The patent remains active with no record of oppositions or re-examinations filed publicly.
-
Maintenance fees are paid through the standard period, and no notable legal challenges have been documented.
-
Some prior art references may have been cited during prosecution, limiting broad claim enforcement in certain jurisdictions.
4. Patent Expiry and Term:
-
Expected expiration: August 25, 2034, assuming no patent term adjustments.
-
The expiration influences market exclusivity and competitive entry strategies.
Implications for R&D and Commercial Strategy
-
The broad compound claims provide a wide scope for related derivatives, but narrow stereochemistry claims could be easily designed around.
-
The method of use claims focus on specific indications, which can be challenged or expanded through additional patent filings.
-
Formulation claims are vital for protecting delivery mechanisms but may be vulnerable if prior art covers similar compositions.
-
The strategic importance lies in maintaining exclusive rights through continued patent filings covering specific formulations or methods of administration.
Key Takeaways
-
US Patent 9,289,391 covers a broad class of compounds with specific therapeutic applications, primarily safeguarding chemical structures, uses, and formulations.
-
The patent landscape includes multiple family members and prior art references, with overlapping claims and claims that hinge on specific structural features.
-
The patent remains enforceable, with no significant legal challenges publicly known, and is set to expire in 2034.
-
Companies should consider narrow claimAround specific stereochemistry or formulations to avoid infringement challenges.
Frequently Asked Questions
1. How broad are the compound claims in US Patent 9,289,391?
They cover a class of chemical structures with specified substituents, providing wide but potentially navigable scope against future derivatives.
2. What are the main limitations of these claims?
Narrower stereochemical claims or specific formulation claims may be more vulnerable to design-around strategies.
3. Are there related patents that could impact freedom to operate?
Yes, multiple filings in global jurisdictions cover similar chemical classes and therapeutic uses, requiring thorough freedom-to-operate analysis.
4. When does the patent expire, and how does this influence market strategies?
Expected expiration is August 25, 2034; market exclusivity diminishes thereafter, opening opportunities for generics and biosimilars.
5. What strategic considerations should R&D teams account for?
Focus on developing formulations or methods outside the patent claims or seek additional patents covering specific derivatives or indications.
References
[1] U.S. Patent Office. (2016). US 9,289,391 B2. Patent documentation.
[2] European Patent Office. Patent family data and filing dates.
[3] WIPO. Patent scope and related filings for chemical compounds.
[4] Patent prosecution history and legal status reports, USPTO.
More… ↓
⤷ Start Trial
|
